MaxCyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte, a prominent commercial cell-engineering company, announced its participation in two upcoming investor conferences. The events include a presentation at the Bank of America 2022 Healthcare Conference on May 11 at 4:40 p.m. PT and a fireside chat at the William Blair 42nd Annual Growth Stock Conference on June 8 at 9:20 a.m. CT. Live and archived webcasts will be accessible on MaxCyte's investor relations website.

The company specializes in advanced cell-based research and has developed innovative platforms, such as the Flow Electroporation technology, to support cell therapy markets.

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

• Bank of America 2022 Healthcare Conference
  Presentation on Wednesday, May 11^th at 4:40 p.m. Pacific Time

• William Blair 42^nd Annual Growth Stock conference
  Fireside chat on Wednesday, June 8^th at 9:20 a.m. Central Time

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

FAQ

What is MaxCyte's stock symbol?

MaxCyte's stock symbol is MXCT.

When is MaxCyte presenting at the Bank of America Healthcare Conference?

MaxCyte will present on May 11, 2022, at 4:40 p.m. Pacific Time.

What is the date and time of MaxCyte's fireside chat at the William Blair Conference?

The fireside chat is scheduled for June 8, 2022, at 9:20 a.m. Central Time.

Where can I find the webcasts for MaxCyte's investor presentations?

Webcasts for MaxCyte's presentations will be available on their investor relations website.

What technologies does MaxCyte focus on?

MaxCyte focuses on cell-engineering technologies, particularly for cell therapy research and development.